blue sky background with sun and lourds - WELCOME TO MY MS FAMILY

Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models

FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical (Mouse Models)

Based on more than a decade of research, Lucid-MS is a patented neuroprotective new chemical entity (“NCE”) that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions. In order to demonstrate the unique potential therapeutic value of this Lucid-MS, the Company has released a video explaining its pre-clinical results, including visual evidence of functional recovery on pre-clinical subjects, which can be accessed here . You can also access the video at www.fsdpharma.com .

The featured study uses an Experimental Autoimmune Encephalitis (“EAE”) mouse model, a commonly used immune-mediated mouse model of MS. MS is typically characterized as an autoimmune disease. Ten days following immunization with the antigen, mice received 1 milligram of Lucid-MS or saline (placebo). Test subjects were monitored for 50 days and were continually assessed for clinical symptoms; those that received Lucid-MS demonstrated an improvement in clinical score, compared with subjects that received placebo. For example, on Day 42, one of the Lucid-MS-treated subjects demonstrated functional recovery with a score of 0.5, compared with a score of 3 on Day 3 (lower clinical score indicates better condition of the subject), and by the end of the study, the subject showed clinical signs similar to those in a healthy mouse (as seen in the video).

“Lucid-MS has demonstrated the potential to prevent the degradation and help re-establish myelin which is evidenced by the functional recovery of mice as well as immunohistochemistry in this study, and several other studies in preclinical animal models,” said Dr. Lakshmi P. Kotra, Ph.D., Chief Executive Officer of Lucid Psycheceuticals Inc. (“Lucid”), FSD Pharma’s wholly-owned subsidiary. “This effect holds good promise for further development as a potential treatment for MS, and the biochemical mechanism of Lucid-MS represents a potential industry first in treating MS. We are eager to advance Lucid-MS to the clinic as quickly as we can.”

FSD Pharma is also advancing the development of its other drug candidates, including Lucid-PSYCH, a psycho-active molecule targeted to treat Major Depressive Disorder, and FSD-PEA, an anti-inflammatory compound.

About FSD Pharma

FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (“FSD BioSciences”) is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Through the Company’s wholly owned subsidiary, Lucid, the Company is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.

Article content

Forward Looking Information

Certain statements contained herein are “forward-looking statements.” Often, but not always, forward-looking statement can be identified by the use of words such as “plans”, “expects”, “expected”, “scheduled”, “estimates”, “intends”, “anticipates”, “hopes”, “planned” or “believes”, or variations of such words and phrases, or states that certain actions, events or results “may”, “could”, “would”, “might”, “potentially” or “will” be taken, occur or be achieved. Forward-looking statements contained in this press release include the comments made with respect to the effects, value and advancement of the Company’s drug candidates, including the further development of drug candidates as a potential treatment for neurodegenerative and mental health disorders such as MS and Major Depressive Disorder, the significance of the Company’s drug candidates to the development of MS treatment in the industry and the Company’s expectations towards the advancement of its drug candidates to clinic. FSD cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Factors that may cause such material differences include without limitation: the fact that the drug development efforts of both Lucid and FSD BioSciences are at a very early stage; the fact that preclinical drug development is uncertain, and the drug product candidates of Lucid and FSD BioSciences may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of Lucid and FSD BioSciences; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of Lucid and FSD BioSciences; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of Lucid and FSD BioSciences; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected, or impacted by COVID-19 related issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of Lucid and FSD BioSciences; and other risks. Further information regarding factors that may cause actual results to differ materially are included in the Company’s annual and other reports filed from time to time with the Canadian Securities Administrators on SEDAR ( www.sedar.com ) and with the U.S. Securities and Exchange Commission on EDGAR ( www.sec.gov ) under the heading “Risk Factors.” Any forward-looking statement contained in this release speaks only as of its date. The Company does not undertake to update any forward-looking statements, except to the extent required by applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005259/en/logo

Contacts

Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc.
Email: Zsaeed@fsdpharma.com
Telephone: (416) 854-8888
Investor Relations: Email: FSDPharma@KCSA.com , skilmer@fsdpharma.com ,
Website: www.fsdpharma.com

Home Adaptations: Simple Changes for Enhanced Accessibility

Creating a home environment that accommodates everyone’s needs, regardless of physical limitations, is a compassionate and necessary endeavor. It involves thoughtful consideration of individual challenges and the strategic implementation of modifications. By focusing on personal requirements, safety, technology, and structural adaptations, you can transform any living space into a sanctuary that promotes independence and ease of living. Here are some tips from My MS Family to get you started!

Stranded

  As I sit here wanting to get my thoughts out, An image of me stranded in a body of stagnant water comes about.   The water is dark and I'm all alone, Holding on to dear life with all its unknown.   I'm cold and numb and not sure what to think. How...

WOODBRIDGE SUPPORT GROUP STARTING UP AGAIN

It’s understandable to feel concerned about how someone might react when you share something personal and sensitive like your diagnosis. However, being open and honest is essential for building trust in any relationship, and if she truly cares for you, she will...

 The Power Within

We have the power to determine our worth. It is time to stop putting ourselves down and realize the value, skills, and creativity that we each can bring to the workplace. Daily, I hear people share with me about their struggles with their self-worth whether it is not...

‘For a better tomorrow’: York Region car show at Bloomington GO Station cuts costs for multiple sclerosis patients

One of York Region’s most acclaimed car shows will return, “bigger and badder” on Saturday, Aug. 31, to display hundreds of amazing four-wheeled vehicles. But it’s two-wheeled vehicles — new powered wheelchairs for their members — that the host group at MS Road to a...

In memory of Deborah Cross

It is with profound sadness that the family of Deborah Cross (neé Richardson) announce her passing on August 31st, 2024, at the age of 68, due to complications from Multiple Sclerosis. She will be lovingly remembered by her daughters, Stephanie Cross (Chris Ling) and...

‘It’s time’: York Region residents with multiple sclerosis want satellite rehab centre and end to barriers

From the moment someone is diagnosed with multiple sclerosis, a maze of barriers awaits. But in York Region, such people aren’t alone. Other residents who also have MS, an auto-immune disease affecting the central nervous system, volunteer to help them buy...

Mavenclad Effect on Quality of Life

Treatment with Mavenclad (cladribine) over two years significantly improved physical and mental health aspects of quality of life in people with highly active relapsing multiple sclerosis, according to a final analysis of data from a Phase 4 study. Mavenclad is an...

2023 Leah Watson Pritchett Recognition Award Recipient

Dear Mirella: Congratulations on receiving the Leah Watson Pritchett Award for 2023. We have been told that you are a selfless member of MY MS Family who volunteers at every event. On many occasions, you have driven members who required mobility assistance to their...

Join our eMailing List

Have you recently been diagnosed with multiple sclerosis or do you care about someone who has?

If you provide your name and email address, we'll send you regular updates about our activities as well as important topics related to life with MS.

Please NOTE: Completing this form gets you on our mailing list but not paid membership status.

If you would like to tap into our membership benefits, please use this link.

* indicates required

We will never share, rent, or sell your personal information. Never gonna happen. You have our word on that.

Become a Volunteer or Donate Today!

Get InvolvedDonate